Clinical evidence shows that AposHealth (an FDA-cleared medical device) improves pain, stiffness, and function in people with knee osteoarthritis.
However, it’s uncertain if these improvements are clinically meaningful. The analyses suggest that AposHealth is cost saving by £1,958 per person when compared with standard care if knee surgery is delayed for 5 years. Because the evidence for the potential cost savings is limited, further data collection is recommended to understand if cost savings are made once AposHealth is used in the NHS.
Recent Posts
Cost-Effectiveness of T1D Screening Effectiveness in Canadian Children
T1D screening effectiveness in the general population substantially outperforms targeted approaches based on family history or genetic risk, according to a new Canadian health economic analysis. General population autoantibody screening detects far more at-risk children than family-history or gen...
Novartis Acquires Mutant-Selective PI3Kα Inhibitor to Enhance Breast Cancer Treatment Options
Novartis has agreed to acquire SNV4818, a pan-mutant-selective PI3Kα inhibitor from Synnovation Therapeutics, targeting PIK3CA mutations...
Semaglutide India Partnership: Enhancing Access to Diabetes Treatment
The Semaglutide India partnership between Lupin Limited and Zydus Lifesciences Limited formalizes a licensing and supply agreement to co-market an innovative Semaglutide Injection (15 mg/3 ml) with a patient-friendly reusable pen device in the Indian market. This collaboration leverages Lupin's e...